Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III

被引:3
作者
Xu, Yu-Yuan [1 ,2 ]
Chen, Wei-Qi [1 ,2 ]
Wang, Meng-Xing [2 ]
Pan, Yue-Song [2 ]
Li, Zi-Xiao [1 ,2 ]
Liu, Li-Ping [1 ,2 ]
Zhao, Xing-Quan [1 ,2 ]
Wang, Yi-Long [1 ,2 ]
Li, Hao [2 ]
Wang, Yong-Jun [1 ,2 ,3 ,4 ]
Meng, Xia [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Res Unit Artificial Intelligence Cerebrovascular D, 2019RU018, Beijing, Peoples R China
[4] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
来源
BMJ OPEN | 2023年 / 13卷 / 03期
基金
中国国家自然科学基金;
关键词
Neurology; Lipid disorders; Stroke medicine; Stroke; SMALL-VESSEL DISEASE; HEMORRHAGIC STROKE; CHOLESTEROL LEVELS; LDL CHOLESTEROL; RISK; STATIN; ATORVASTATIN; ORGANIZATION; PREVENTION; ETHNICITY;
D O I
10.1136/bmjopen-2022-069465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesThe aims of the study were to assess the management of low-density lipoprotein cholesterol (LDL-C) and the goal achievement, as well as to investigate the association between baseline LDL-C level, lipid-lowering treatment (LLT), and stroke recurrence in patients with ischaemic stroke or transient ischaemic attack (TIA).DesignOur study was a post hoc analysis of the Third China National Stroke Registry (CNSR-III).SettingWe derived data from the CNSR-III - a nationwide clinical registry of ischaemic stroke and TIA based on 201 participating hospitals in mainland China.Participants15,166 patients were included in this study with demographic characteristics, etiology, imaging, and biological markers from August 2015 to March 2018.Primary and secondary outcome measuresThe primary outcome was a new stroke, LDL-C goal (LDL-C<1.8mmol/L and LDL-C<1.4mmol/L, respectively) achievement rates, and LLT compliance within 3, 6, and 12 months. The secondary outcomes included major adverse cardiovascular events (MACE) and all caused death at 3 and 12 months.ResultsAmong the 15,166 patients, over 90% of patients received LLT during hospitalization and 2 weeks after discharge; the LLT compliance was 84.5% at 3 months, 75.6% at 6 months, and 64.8% at 12 months. At 12 months, LDL-C goal achievement rate for 1.8mmol/L and 1.4mmol/L was 35.4% and 17.6%, respectively. LLT at discharge was associated with reduced risk of ischemic stroke recurrence (HR=0.69, 95% CI: 0.48-0.99, p=0.04) at 3 months. The rate of LDL-C reduction from baseline to 3-month follow-up was not associated with a reduced risk of stroke recurrence or major adverse cardiovascular events (MACE) at 12 months. Patients with baseline LDL-C <= 1.4mmol/L had a numerically lower risk of stroke, ischemic stroke and MACE at both 3 months and 12 months.ConclusionsThe LDL-C goal achievement rate has increased mildly in the stroke and TIA population in mainland China. Lowered baseline LDL-C level was significantly associated with a decreased short- and long-term risk of ischemic stroke among stroke and TIA patients. LDL-C<1.4mmol/L might be a safe standard for this population.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
    Amarenco, P.
    Kim, J. S.
    Labreuche, J.
    Charles, H.
    Abtan, J.
    Bejot, Y.
    Cabrejo, L.
    Cha, J-K
    Ducrocq, G.
    Giroud, M.
    Guidoux, C.
    Hobeanu, C.
    Kim, Y. J.
    Lapergue, B.
    Lavallee, P. C.
    Lee, B-C
    Lee, K-B
    Leys, D.
    Mahagne, M-H
    Meseguer, E.
    Nighoghossian, N.
    Pico, F.
    Samson, Y.
    Sibon, I
    Steg, P. G.
    Sung, S-M
    Touboul, P. J.
    Touze, E.
    Varenne, O.
    Vicaut, E.
    Yelles, N.
    Bruckert, E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) : 9 - 19
  • [2] Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes
    Amarenco, Pierre
    Kim, Jong S.
    Labreuche, Julien
    Giroud, Maurice
    Lee, Byung-Chul
    Mahagne, Marie-Helene
    Nighoghossian, Norbert
    Simon, Tabassome
    Steg, Philippe Gabriel
    Touboul, Pierre-Jean
    Vicaut, Eric
    Yelles, Nessima
    Bruckert, Eric
    [J]. EUROPEAN STROKE JOURNAL, 2019, 4 (03) : 271 - 280
  • [3] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [4] Collins R, 2004, LANCET, V363, P757
  • [5] Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services
    Coull, AJ
    Lovett, JK
    Rothwell, PM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7435): : 326 - 328
  • [6] Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
    Giugliano, Robert P.
    Pedersen, Terje R.
    Saver, Jeffrey L.
    Sever, Peter S.
    Keech, Anthony C.
    Bohula, Erin A.
    Murphy, Sabina A.
    Wasserman, Scott M.
    Honarpour, Narimon
    Wang, Huei
    Lira Pineda, Armando
    Sabatine, Marc S.
    [J]. STROKE, 2020, 51 (05) : 1546 - 1554
  • [7] 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
    Kleindorfer, Dawn O.
    Towfighi, Amytis
    Chaturvedi, Seemant
    Cockroft, Kevin M.
    Gutierrez, Jose
    Lombardi-Hill, Debbie
    Kamel, Hooman
    Kernan, Walter N.
    Kittner, Steven J.
    Leira, Enrique C.
    Lennon, Olive
    Meschia, James F.
    Nguyen, Thanh N.
    Pollak, Peter M.
    Santangeli, Pasquale
    Sharrief, Anjail Z.
    Smith, Sidney C., Jr.
    Turan, Tanya N.
    Williams, Linda S.
    [J]. STROKE, 2021, 52 (07) : E364 - E467
  • [8] Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
    Klijn, Catharina J. M.
    Paciaron, Maurizio
    Berge, Eivind
    Korompoki, Eleni
    Korv, Janika
    Lal, Avtar
    Putaala, Jukka
    Werring, David J.
    [J]. EUROPEAN STROKE JOURNAL, 2019, 4 (03) : 198 - 223
  • [9] Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
  • [10] Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
    McKenney, James M.
    Koren, Michael J.
    Kereiakes, Dean J.
    Hanotin, Corinne
    Ferrand, Anne-Catherine
    Stein, Evan A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (25) : 2344 - 2353